Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2216-2225

  Lalani, Alshad S ^a   Alters, Susan E ^a   Wong, Alvin ^a   Albertella, Mark R ^b   Cleland, Jeffrey L ^a   Henner, William David ^a  

^a Novacea Inc   (United States)

^b KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AQ4; DRUG METABOLITE; GEMCITABINE; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; XENOGRAFT;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PRODRUGS;

EID: 34247517825     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2427     Document Type: Article

References (49)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
3. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
4. Williams KJ, Cowen RL, Brown LM, et al. Hypoxia in tumors: molecular targets for anti-cancer therapeutics. Adv Enzyme Regul 2004;44:93-108.
5. American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society; 2006.
6. Raijman I, Levin B. Exocrine tumors of the pancreas. In: Go VLM, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, editors. Pancreas: biology, pathology, and diseases. New York: Raven Press; 1993. p. 899-912.
7. Ranniger K, Saldino RM. Arteriographic diagnosis of pancreatic lesions. Radiology 1966;86:470-4.
8. Yassa NA, Yang J, Stein S, Johnson M, Ralls P. Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. J Clin Ultrasound 1997;25:473-80.
9. Megibow AJ. Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions. Radiology 1992;183:297-303.
10. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
11. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
12. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47.
13. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23: 293-310.
14. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
15. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
16. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 2004;18: 2183-94.
17. Buchler P, Reber HA, Lavey RS, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 2004;120:295-303.
18. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
19. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance, and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
20. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-93.
21. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34:581-92.
22. McKeown SR, Hejmadi MV, Mclntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 1995; 72:76-81.
23. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 1993;12:119-34.
24. Smith PJ, Blunt NJ, Desnoyers R, Giles Y, Patterson LH. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 1997;39:455-61.
25. Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 1998;42:763-7.
26. Raleigh SM, Wanogho E, Burke MD, Patterson LH. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica 1999;29:1115-22.
27. Patterson LH, McKeown SR, Robson T, et al. Anti-tumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 1999;14:473-86.
28. McErlane V, Yakkundi A, McCarthy HO, et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 2005;7:851-9.
29. Yakkundi A, McErlane V, Murray M, et al. Tumor-selective drug activation: a GDEPTapproach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 2006;13:598-605.
30. McCarthy HO, Yakkundi A, McErlane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther 2003; 10:40-8.
31. Wilson WR, Denny WA, Pullen SM, et al. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide, and AQ4N. Br J Cancer Suppl 1996;27:S43-7.
32. Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004;4:257-65.
33. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8: 1335-47.
34. Smith PJ, Desnoyers R, Blunt N, et al. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 1997;27:43-53.
35. Patterson LH, Craven MR, Fisher GR, Teesdale-Spittle P. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res 1994;6: 533-8.
36. Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung, and pancreatic xenograft models. Invest New Drugs 1996;14:243-7.
37. Mathieu A, Remmelink M, D'Haene N, et al. Development of a chemoresistant orthotopic human non-small cell lung carcinoma model in nude mice: analyses of tumor heterogeneity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-α (GST)-α, GST-μ, and GST-π. Cancer 2004;101:1908-18.
38. Swaine DJ, Loadman PM, Bibby MC, Graham MA, Patterson LH. High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide. J Chromatogr B Biomed Sci Appl 2000;742:239-45.
39. Bouvet M, Wang J, Nardin SR, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res 2002;62:1534-40.
40. Patterson LH, McKeown SR, Ruparelia K, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000;82:1984-90.
41. Loadman PM, Swaine DJ, Bibby MC, Welham KJ, Patterson LH. A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab Dispos 2001;29:422-6.
42. Friery OP, Gallagher R, Murray MM, et al. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 2000;82:1469-73.
43. Gallagher R, Hughes CM, Murray MM, et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001;85:625-9.
44. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
45. Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ.Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res 2005;11:4212-6.
46. Harris PA, Dunk CR, Albertella MR, et al. Tumour-specific activation of the hypoxic cell cytotoxin AQ4N: a phase 1 clinical study in solid tumors. Proc Amer Assoc Cancer Res 2006;47:571-2.
47. Benghiat A, Steward WP, Middleton M, et al. The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT). J Clin Oncol 2005;23:105s.
48. Benghiat A, Steward WP, Loadman PM, et al. Phase I dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): first report. J Clin Oncol 2004;22:149s.
49. Sarantopoulos J, Tolcher AW, Wong A, et al. Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: the results of a phase I study using an accelerated dose escalation. J Clin Oncol 2006;24:81s.